Target intelligence / Profile preview

Glutamate receptor ionotropic, kainate 3 (GRIK3)

Target
GRIK3
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel
01

Overview

Glutamate receptor ionotropic, kainate 3 (GRIK3, also known as GluK3 or GluR7) is a ligand-gated ion channel that belongs to the kainate subfamily of ionotropic glutamate receptors. It functions as a cation-permeable channel activated by the binding of L-glutamate and kainic acid, converting chemical signals into electrical impulses at excitatory synapses in the central nervous system. GRIK3 is widely expressed in the brain, particularly in the neocortex and dentate gyrus of the hippocampus, where it plays a critical role in synaptic transmission, presynaptic facilitation, and synaptic plasticity.

Dysregulation or genetic polymorphisms of GRIK3, such as the Ser310Ala variant, have been linked to various neuropsychiatric and neurodegenerative disorders, including schizophrenia, major depressive disorder, epilepsy, and alcohol dependence. Additionally, aberrant overexpression of GRIK3 has been implicated in several malignancies, such as breast and colorectal cancers, where it promotes cell proliferation, migration, and epithelial-mesenchymal transition. Pharmacological targeting of GRIK3 involves agonists like glutamic acid and kainic acid, antagonists like UBP310 and quinoxalinedione derivatives, and positive allosteric modulators like BPAM344, making it an attractive therapeutic target for both neurological conditions and oncology.

Other names
GluK3GLUR7GluR-7EAA5Excitatory amino acid receptor 5Glutamate receptor 7Glutamate ionotropic receptor kainate type subunit 3
02

Mechanism of action

Drugs targeting GRIK3 act primarily as agonists, antagonists, or allosteric modulators. Agonists like glutamic acid and kainic acid bind to the ligand-binding domain, inducing a conformational change that opens the cation channel to allow sodium and calcium influx. Antagonists, such as UBP310 or quinoxalinedione derivatives, competitively block agonist binding to inhibit channel activation. Positive allosteric modulators, such as BPAM344, bind to the dimer interface of the ligand-binding domain, stabilizing it to slow desensitization and potentiate receptor currents.

03

Biological functions

Signal transductionSynaptic transmissionIon transportRegulation of membrane potentialSynaptic plasticity
04

Disease associations

Neurodegenerative diseaseCancerNeuropsychiatric disorderEpilepsySchizophreniaDepressionAlcohol dependence
05

Safety considerations

NeurotoxicitySeizuresCognitive impairmentNephrotoxicity (associated with some quinoxalinedione antagonists like NBQX)Psychiatric side effects
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

GRIK3 Ser310Ala polymorphismGRIK3 methylationGRIK3 expression level

Beyond the preview

Go deeper on Glutamate receptor ionotropic, kainate 3 (GRIK3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic, kainate 3 (GRIK3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call